Literature DB >> 19913808

Eligibility for active surveillance and pathological outcomes for men undergoing radical prostatectomy in a large, community based cohort.

Marc C Smaldone1, Janet E Cowan, Peter R Carroll, Benjamin J Davies.   

Abstract

PURPOSE: We analyzed competing active surveillance criteria in men who underwent radical prostatectomy in relation to outcome data in a large, community based cohort.
MATERIALS AND METHODS: We identified all men from the CaPSURE database who underwent radical prostatectomy from 1999 to 2007 and met inclusion criteria for the stringent prospective University of California-San Francisco and Johns Hopkins active surveillance protocols. Rates of pathological upgrading, up staging and biochemical recurrence were compared.
RESULTS: We identified 2,837 men who underwent radical prostatectomy and had complete pathological and followup data available. Of these men 1,375 and 125 met University of California-San Francisco and Johns Hopkins criteria, respectively. When comparing men who met the 2 sets of criteria vs those who met University of California-San Francisco criteria only, there were no significant differences in the rate of upgrading (20% vs 27%, p = 0.07) and up staging (6% vs 8%, p = 0.39) at radical prostatectomy. At a median 36-month followup 5-year biochemical recurrence-free estimates were similar at 92% in men who met the 2 sets of criteria and 90% in those who met the University of California-San Francisco definition only. On multivariate analysis upgrading to 7 or greater (HR 2.2, 95% CI 1.2-4.2), up staging (HR 3.5, 95% CI 1.3-9.3), and upgrading plus up staging (HR 6.9, 95% CI 3.3-14.5) were associated with a higher risk of biochemical recurrence in patients who met University of California-San Francisco criteria.
CONCLUSIONS: Men who met enrollment criteria for the 2 active surveillance protocols had a similar rate of upgrading, up staging and 5-year biochemical recurrence-free rates after radical prostatectomy. Further comparison between current protocols is warranted to establish universal inclusion criteria.

Entities:  

Mesh:

Year:  2010        PMID: 19913808     DOI: 10.1016/j.juro.2009.08.152

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  11 in total

Review 1.  Active surveillance for favorable-risk prostate cancer: background, patient selection, triggers for intervention, and outcomes.

Authors:  Laurence Klotz
Journal:  Curr Urol Rep       Date:  2012-04       Impact factor: 3.092

2.  Predictive models for worsening prognosis in potential candidates for active surveillance of presumed low-risk prostate cancer.

Authors:  Prasanna Sooriakumaran; Abhishek Srivastava; Paul Christos; Sonal Grover; Maria Shevchuk; Ashutosh Tewari
Journal:  Int Urol Nephrol       Date:  2011-06-26       Impact factor: 2.370

3.  Age at diagnosis on prostate cancer survival undergoing androgen deprivation therapy as primary treatment in daily practice: results from Japanese observational cohort.

Authors:  Teruo Inamoto; Haruhito Azuma; Shiro Hinotsu; Taiji Tsukamoto; Mototsugu Oya; Osamu Ogawa; Tadaichi Kitamura; Suzuki Kazuhiro; Seiji Naito; Mikio Namiki; Kazuo Nishimura; Yoshihiko Hirao; Michiyuki Usami; Masaru Murai; Hideyuki Akaza
Journal:  J Cancer Res Clin Oncol       Date:  2014-03-28       Impact factor: 4.553

4.  Outcomes of active surveillance for men with intermediate-risk prostate cancer.

Authors:  Matthew R Cooperberg; Janet E Cowan; Joan F Hilton; Adam C Reese; Harras B Zaid; Sima P Porten; Katsuto Shinohara; Maxwell V Meng; Kirsten L Greene; Peter R Carroll
Journal:  J Clin Oncol       Date:  2010-11-29       Impact factor: 44.544

5.  Validation of Selection Criteria for Active Surveillance in Prostate Cancer.

Authors:  Saif Elamin; Nikita Rajiv Bhatt; Niall F Davis; Paul Sweeney
Journal:  J Clin Diagn Res       Date:  2016-04-01

6.  Expressed prostatic secretion biomarkers improve stratification of NCCN active surveillance candidates: performance of secretion capacity and TMPRSS2:ERG models.

Authors:  Christopher Whelan; Mark Kawachi; David D Smith; Jennifer Linehan; Gail Babilonia; Rosa Mejia; Timothy Wilson; Steven S Smith
Journal:  J Urol       Date:  2013-05-10       Impact factor: 7.450

7.  Relationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance.

Authors:  A F Kotb; S Tanguay; M A Luz; W Kassouf; A G Aprikian
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-10-12       Impact factor: 5.554

Review 8.  The Study of Active Monitoring in Sweden (SAMS): a randomized study comparing two different follow-up schedules for active surveillance of low-risk prostate cancer.

Authors:  Ola Bratt; Stefan Carlsson; Erik Holmberg; Lars Holmberg; Eva Johansson; Andreas Josefsson; Annika Nilsson; Maria Nyberg; David Robinsson; Jonas Sandberg; Dag Sandblom; Pär Stattin
Journal:  Scand J Urol       Date:  2013-07-24       Impact factor: 1.612

9.  Predictive factors of unfavorable prostate cancer in patients who underwent prostatectomy but eligible for active surveillance.

Authors:  Seol Ho Choo; Hwang Gyun Jeon; Byong Chang Jeong; Seong Il Seo; Seong Soo Jeon; Han Yong Choi; Hyun Moo Lee
Journal:  Prostate Int       Date:  2014-06-30

10.  Can Prostate-Specific Antigen Kinetics before Prostate Biopsy Predict the Malignant Potential of Prostate Cancer?

Authors:  Sang Jin Kim; Tae Yoong Jeong; Dae Seon Yoo; Jinsung Park; Seok Cho; Seok Ho Kang; Sang Hyub Lee; Seung Hyun Jeon; Tchun Yong Lee; Sung Yul Park
Journal:  Yonsei Med J       Date:  2015-11       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.